New basic science initiatives with the angiotensin II receptor blocker valsartan

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 1, Issue SUPPL. 2, 2000, Pages 3-5

  De Gasparo, Marc ^a,b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NONE   (Switzerland)

Author keywords

AT1 receptor blocker; Cell proliferation; Cholesterol uptake; Endothelial dysfunction; Preclinical data; Vasoconstriction

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE; VALSARTAN;

ANIMAL; ATHEROSCLEROSIS; CELL PROLIFERATION; DRUG EFFECT; HEART VENTRICLE REMODELING; HUMAN; INFLAMMATION; PATHOLOGY; REVIEW; VASCULAR ENDOTHELIUM; VASOCONSTRICTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; ATHEROSCLEROSIS; CELL PROLIFERATION; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; TETRAZOLES; VALINE; VASOCONSTRICTION; VENTRICULAR REMODELING;

EID: 0346677463     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2000.052     Document Type: Article

References (13)

1. Pool J, Oparil S, Hedner T et al. Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker. Clin Ther 1998;20:1106-14.
2. Shetty SS, DelGrande D. Differential inhibition of the pre-junctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan. J Pharmacol Ext Ther 2000; 294: 179-86.
3. Tong CF, Ying WY, Hua RY et al. Effect of valsartan and captopril in rabbit carotid injury: possible involvement of bradykinin in the antiproliferative action of the renin-angiotensin blockade. JRAAS (in press).
4. 1 receptor antagonist. Amer J Pathol 1991;139:1291-6.
5. Ledingham JM, Laverty R. Remodelling of resistance arteries in genetically hypertensive rats by treatment with valsartan, an angiotensin II receptor antagonist. Clin Exp Pharmacol Physiol 1996;23:576-8.
6. Loging JA, New RB, Baicu SC et al. Effects of angiotensin type-I receptor blockade on pericardial fibrosis. J Surg Res 1999;87:101-7.
7. 1-receptor antagonist, on angiotensin II-induced PAI-1 biosynthesis in smooth muscle cells. Hypertension (in press).
8. De La Heras N, Vazques-Pérez S, Navarro-Cid J et al. Angiotensin II type 1 receptor antagonism prevented the effects of hypercholesterolemia on plasma fibrinolytic balance in rabbits. High Blood Pressure Council, Washington October 2000. Hypertension 2000;36:694 (abstract).
9. Mervaala EM, Muller DN, Park JK et al. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension 1999;33:389-95.
10. Hilgers KF, Hartner A, Porst M et al. Monocyte chemoattractant protein-1 and macrophage infiltration in hypertensive kidney injury: role of the angiotensin II type 1 receptor. Kidney Int 2000;58:2408-19.
11. de las Heras N, Aragoncillo, P, Maeso R et al. AT(1) receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits. Hypertension 1999;34: 969-75.
12. Scheidegger KJ, Butler S, Witztum JL. Angiotensin II increases macrophage-mediated modification of low-density lipoprotein via a lipoxygenase-dependent pathway. J Biol Chem 1997;272:21609-15.
13. de Gasparo M, Hess P, Nuesslein-Hildesheim B et al. Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction. JRAAS 2000;1;151-8.